In vitro tests for haematotoxicity: Prediction of drug-induced myelosuppression by the CFU-GM assay

Alternatives to Laboratory Animals

Volumn 30, Issue SUPPL. 2, 2002, Pages 75-79

  Pessina, Augusto ^a   Albella, Beatriz ^b   Bayo, Maria ^a   Bueren, Juan ^b   Brantom, Paul ^c   Casati, Silvia ^d   Croera, Cristina ^a   Parchment, Ralph ^e   Parent Massin, Dominique ^f   Schoeters, Greet ^g   Sibiri, Yann ^f   Van Den Heuvel, Rosette ^g   Gribaldo, Laura ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b CIEMAT   (Spain)

^c BIBRA INTERNATIONAL   (United Kingdom)

^d JOINT RESEARCH CENTRE   (Italy)

^e WAYNE STATE UNIVERSITY   (United States)

^f Technopôle   (France)

^g FLEMISH INSTITUTE FOR TECHNOLOGICAL RESEARCH VITO   (Belgium)

Author keywords

Acute neutropenia; CFU GM assay; Maximum tolerated dose; Myelotoxicity

Indexed keywords

ACICLOVIR; BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORPROMAZINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; INDOMETACIN; LINDANE; METHOTREXATE; PACLITAXEL; TENIPOSIDE; TIOGUANINE; XENOBIOTIC AGENT; ZIDOVUDINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TESTING ALTERNATIVE; ASSAY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; COLONY FORMING UNIT GM; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY;

ANIMALIA;

EID: 12244260747     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119290203002s11     Document Type: Conference Paper

References (16)

1. Balls, M., Blaauboer, B.J., Fentem, J.H., Bruner, L., Combes, R.D., Ekwall, B., Fielder, R.J., Guillouzo, A., Lewis, R.W., Lovell, D.P., Reinhardt, C.A., Repetto, G., Sladowski, D., Spielmann, H. & Zucco, F. (1995). Practical aspects of the validation of toxicity test procedures. The report and recommendations of ECVAM workshop 5. ATLA 23, 129-147.
2. Curren, R.D., Southee, J.A., Spielmann, H., Liebsch, M., Fentem, J.H. & Balls, M. (1995). The role of prevalidation and validation in the development, validation and acceptance of alternative methods. ECVAM Prevalidation Task Force Report 1. ATLA 23, 409-470.
3. Du, D.L., Volpe, D.A., Grieshaber, C.K. & Murphy, M.J., Jr (1990). Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human haematopoietic cells in vitro. Cancer Research 50, 4038-4043.
4. Deldar, A. & Stevens, C.E. (1993). Development and application of in vitro models of haematopoiesis to drug development. Toxicologic Pathology 21, 231-240
5. Gribaldo, L., Bueren, J., Deldar, A., Okland, P., Meredith, C., Moneta, D., Mosesso, P., Parchment, R., Parent-Massin, D., Pessina, A., San Roman, J. & Schoeters, G. (1996). The use of in vitro systems for evaluating haematotoxicity. ATLA 24, 211-231
6. Metcalf D. (1984). The basic biology of haematopoiesis. In The Haematopoietic Colony Stimulating Factors (ed. D. Metcalf), pp. 1-26. Amsterdam, The Netherlands: Elsevier.
7. Grande, T. & Bueren, J.A. (1995). Analysis of the haematopoiesis in mice irradiated with 500mGy of X-rays at different stages of development. Radiation Research 143, 327-333
8. Bruce, W.R., Meeker, B.E. & Valeriote, F.A. (1966). Comparison of the sensitivity of normal haematopoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo. Journal of the National Cancer Institute 37, 233-245
9. Parchment, R.E., Gordon, M., Grieshaber, C.K., Sessa, C., Volpe, D. & Ghielmini, M. (1998). Predicting haematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Annals of Oncology 9, 357-364.
10. Parchment, R.E. (2000). Oncology clinical trials and in vitro prediction models for xenobiotic toxicology. Developments in Animal Veterinary Science 31, 693-708.
11. Bradley, T.R. & Metcalf, D. (1966). The growth of mouse bone marrow cells in vitro. Australian Journal of Experimental Biology and Medical Science 44, 287-300
12. Pessina, A., Albella, B., Bueren, J., Brantom, P., Casati, S., Gribaldo, L., Croera, C., Gagliardi, G., Foti, P., Parchment, R., Parent-Massin, D., Sibiril, Y., Schoeters, G. & Van Den Heuvel, R. (2001). Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicology in Vitro 15, 729-740.
13. Parchment, R.E., Huang, M. & Erickson-Miller, C.L. (1993). Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicologic Pathology 21, 241-250.
14. Parchment, R.E., Volpe, D.A., LoRusso, P.M., Erickson-Miller, C.L., Huang, M., Murphy, M.J., Jr & Grieshaber, C.K. (1994). An in vivo-in vitro correlation of the myelotoxicity of 9-methoxypyrazoloacridine (PZA, NSC-366140, PD115934) to myeloid and erythroid haematopoietic progenitors from human, murine and canine marrow. Journal of the National Cancer Institute 86, 273-280.
15. Volpe, D.A., Tomaszewski, J.E., Parchment, R.E., Garg, A., Flora, K.P., Murphy, M.J., Jr & Grieshaber, C.K. (1996). Myelotoxic effects of the bifunctional alkylating agent bizelesin to human, canine, and murine myeloid progenitor cells. Cancer Chemotherapy and Pharmacology 39, 143-149.
16. Erickson-Miller, C.L., May, R., Tomaszewski, J., Osborn, B., Murphy, M.J., Jr, Page, J.G. & Parchment, R.E. (1997). Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemotherapy and Pharmacology 39, 467-472.